STRO
$22.93
Sutro Biopharma, Inc.
Recent News
Arcturus Therapeutics (ARCT) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -11.71% and -49.91%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Sutro Biopharma (STRO) Surges 11.9%: Is This an Indication of Further Gains?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Sutro Biopharma, Inc. (NASDAQ:STRO) has caught the attention of institutional investors who hold a sizeable 41% stake
Key Insights Institutions' substantial holdings in Sutro Biopharma implies that they have significant influence over...
Sutro Biopharma (STRO) Soars 5.9%: Is Further Upside Left in the Stock?
Sutro Biopharma (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Sutro Biopharma (NASDAQ:STRO) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...